| Literature DB >> 26934405 |
Abstract
α-smooth muscle actin, encoded by ACTA2 gene, is an isoform of the vascular smooth muscle actins, typically expressed in the vascular smooth muscle cells contributing to vascular motility and contraction. ACTA2 gene mutations cause a diversity of diffuse vasculopathies such as thoracic aortic aneurysms and dissections as well as occlusive vascular diseases, including premature coronary artery disease and ischemic stroke. Dynamics of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells and proliferation of the proteins have been well described. Although a variety of research works have been undertaken in terms of modifications of α-smooth muscle actin and mutations of ACTA2 gene and myosin, the underlying mechanisms towards the pathological processes by way of gene mutations are yet to be clarified. The purpose of the present article is to describe the phenotypes of α-smooth muscle actin and implications of ACTA2 mutations in vasculopathies in order to enhance the understanding of potential mechanisms of aortic and coronary disorders.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26934405 PMCID: PMC4762557 DOI: 10.5935/1678-9741.20150081
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1The relationship among smooth muscle actin, ACTA2 gene and contractile property in vasculopathies. The contractility of the smooth muscle cells is maintained via cyclic interactions between α-smooth muscle actin (encoded by ACTA2) and the β-myosin heavy chain (encoded by MYH11). Missense mutations in ACTA2 and myosin are responsible for the development of syndromic aneurysms or occlusive vascular disorders, depending on the vascular pathology of either medial smooth muscle cell hypoplasia or medial proliferation. ACTA2=actin, alpha 2, smooth muscle, aorta; CAD=coronary artery disease; MYH11=myosin heavy chain 11; SMA=smooth muscle actin; SMC=smooth muscle cell; TAAD=thoracic aortic aneurysm and dissection
Causative ACTA2 gene mutations of vasculopathies.
| Causative gene mutation | Typical manifestation | Reference |
|---|---|---|
| p.Arg64Lys (c.191G>A) (exon 3), p.Arg179Cys (c.535C>T) (exon 6) & p.Lue244Phe (c.732G>T) (exon 7) | TAAD | [23] |
| p.Arg179His | TAAD | [23] |
| G304R (in the vicinity of the ATP-binding site) | TAAD, isolated | [20] |
| p.G152_T205del (c.616+1G>T), p.R212Q & p.R149C | TAAD, familial | [17] |
| p.Y145C | TAAD, sporadic & young-onset | [17] |
| c.76G>T; p.Asp26Tyr | TAAD, non-syndromic familial | [19] |
| R39C (the DNAse-I-binding loop within subdomain 2 of a-smooth muscle actin) | Aortic aneurysm, recurrent | [20] |
| M49V (the DNAse-I-binding loop within subdomain 2 of a-smooth muscle actin) R118Q & R149C | Aortic dissection | [20] |
| R118Q & R149C | Aortic disease, coronary artery disease (early onset) | [15] |
| R258 | Aortic disease, patent ductus arteriosus, cerebrovascular disease (very early onset), including Moyamoya disease | [15] |
| R179H | Aortic & cerebrovascular disease, fixed dilated pupils, hypotonic bladder, gut malrotation, hypoperistalsis & pulmonary hypertension | [15] |
| R179H | More severe vasculopathy, thoracic aortic aneurysm & brachial artery occlusion | [16,18] |
| p.R118Q, p.R149C | Coronary artery disease | |
| p.R179C amino acid substitution (c.535C>T in exon 6) | Primary pulmonary hypertension, persistent ductus arteriosus, extensive cerebral white matter lesions, fixed dilated pupils, intestinal malrotation & hypotonic bladder | [31] |
| c.772C/T, p.R258C; c.773 G/A, p.R258H; R179H, c.536 G/R (Exon 6) | Moyamoya disease | [33] |
| p.R258C/H | Strokes | |
| p.R39H (SD2 domain) | Stroke (before the age of 20) | |
| R179H substitutions | Cerebral developmental defects (underdeveloped corpus callosum & vermis hypoplasia), vascular fragility & ductus arteriosus rupture | [31] |
| R179H | Neonatal seizures due to multifocal infarcts, asymmetric motor deficits, global developmental delay, spasticity, congenital bilateral mydriasis & patent ductus arteriosus | [30] |
| p.R149C, p.R118Q & p.T353N (within the hydrophobic cleft of a-smooth muscle actin) | Premature coronary artery disease | |
| p.R185Q | Perturb adenosine triphosphatase hydrolysis | |
| R149C | Skin rash caused by dermal capillary and small artery occlusion referring to as livedo reticularis & with iris flocculi, patent ductus arteriosus & bicuspid aortic valve |
ATP=adenosine triphosphate; TAAD=thoracic aortic aneurysm and dissection.
|
| |
|---|---|
| ACTA2 | = Actin, alpha 2, smooth muscle, aorta |
| bFGF | = Basic fibroblast growth factor |
| CAD | = Coronary artery disease |
| HH | = Hamburger - Hamilton stage |
| MYH11 | = Myosin heavy chain 11 |
| MYLK | = Myosin light chain kinase |
| PDGF | = Platelet derived growth factor |
| SMA | = a-smooth muscle actin |
| SMCs | = Smooth muscle cells |
| TAAD | = Thoracic aortic aneurysm and dissection |
| TGF | = Transforming growth factor |
| TGF-β1 | = Transforming growth factor beta 1 |
| TGFβR1 | = Transforming growth factor beta-receptor 1 |
| TGFβR2 | = Transforming growth factor beta-receptor 2 |
|
| |
|---|---|
| SMY | Study conception and design; analysis and/or interpretation of data; manuscript writing, final approval of the manuscript. |